Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Loxo up 15% ahead of data presentation on RET inhibitor LOXO-292

Published 09/13/2017, 11:12 AM
Updated 09/13/2017, 11:12 AM
© Reuters.  Loxo up 15% ahead of data presentation on RET inhibitor LOXO-292
  • Giddy investors have bid up Loxo Oncology (LOXO +15.4%) ahead of next month's presentation of initial clinical data on LOXO-292 at a lung cancer conference in Japan. The data, to be presented on October 18, will include case reports from two RET fusion-positive lung cancer patients who were previously treated with multikinase inhibitors.
  • Phase 1-stage LOXO-292 inhibits RET (rearranged during transfection) kinase. RET fusions occur in ~60% of medullary thyroid cancer cases, as much as 20% of papillary thyroid cancer cases and ~2% of non-small cell lung cancers. RET-expressing tumors, which depend on the kinase for proliferation and survival, are highly sensitive small molecule RET inhibitors.
  • Now read: ROTY Volume 1 Edition 27: Spring Bank And Anaptysbio Making Moves Higher + A New Pilot Purchase


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.